Mylan found liable for Savella patent infringement

A US court has sided with Forest Laboratories in a dispute with Mylan Pharmaceuticals centring on the Savella (milnacipran) drug.

In a judgment handed down on Monday, July 11, the US District Court for the District of Delaware said Mylan infringed three patents related to the drug, used for the treatment of fibromyalgia.

The dispute began in March 2014 after Mylan filed an Abbreviated New Drug Application with the US Food and Drug Administration seeking approval to market a generic version of the drug.

Forest sued Mylan the following month alleging infringement of three patents it owns covering the drug, US numbers 6,602,911; 7,888,342 and 7,994,220.

Mylan claimed that the patents were invalid and it should therefore be able to produce the generic.

But the court found in favour of Forest ruling that the three patents were valid and had been infringed by Mylan.

Fibromyalgia is a rheumatic condition characterised by muscular pain with stiffness and tenderness on specific parts of the body.